AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Dyne Therapeutics Inc. (DYN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

14.01

0.19 (1.37%)

At close: Feb 20, 2025, 3:59 PM

14.00

-0.07%

After-hours: Feb 20, 2025, 05:02 PM EST

undefined% (undefined)

Bid	13.43
Market Cap	1.43B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.58
PE Ratio (ttm)	-3.91
Forward PE	n/a
Analyst	Buy

Ask	14.49
Volume	542,951
Avg. Volume (20D)	1,709,972
Open	13.85
Previous Close	13.82
Day's Range	13.63 - 14.24
52-Week Range	13.07 - 47.45
Beta	undefined

About DYN

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therape...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 17, 2020

Employees 173

Stock Exchange NASDAQ

Ticker Symbol DYN

Website https://www.dyne-tx.com

Full Company Profile

Analyst Forecast

According to 10 analyst ratings, the average rating for DYN stock is "Buy." The 12-month stock price forecast is $52, which is an increase of 271.16% from the latest price.

Buy 90.00%

Hold 10.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

4 weeks ago

-2.98%

Dyne Therapeutics shares are trading higher after ... Unlock content with Pro Subscription

1 month ago

-3.35%

Dyne Therapeutics shares are trading higher after the company announced it will release new clinical data from its Phase 1/2 ACHIEVE trial.

News

1 week ago · zacks.com

After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN)

Dyne Therapeutics (DYN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in r...

3 weeks ago · zacks.com

5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era

Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, DYN, NKTR and CRDL may prove to be good additions to one's portfolio.

3 weeks ago · zacks.com

Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround

1 month ago · benzinga.com

Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday?

On Friday, Dyne Therapeutics, Inc. DYN revealed new data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1).